查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594387

骨髓發育不良症候群市場：按給藥途徑、藥物類別分類 - 2025-2030 年全球預測

Myelodysplastic Syndrome Market by Route of Administration (Oral, Parenteral), Drug Class (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

骨髓發育不良症候群市場價值2023年為25.9億美元，預計到2024年將達到28.4億美元，複合年成長率為10.07%，預計到2030年將達到50.7億美元。

骨髓發育不良症候群(MDS) 是一組不同的骨髓疾病，其特徵是造血功能低下，導致血球異常。該領域的分析範圍包括了解診斷方法、治療方法和患者人口統計數據，這對於制定有針對性的行銷策略至關重要。對MDS進行研究的必要性源自於MDS盛行率的增加，特別是在人口老化中，以及中等存活率，這需要更好的治療方法。最終用途範圍包括管理 MDS 治療和護理的醫院、癌症中心和專科診所。

主要市場統計
基準年[2023] 25.9億美元
預測年份 [2024] 28.4億美元
預測年份 [2030] 50.7億美元
複合年成長率（%） 10.07%

根據市場洞察，在藥物開發的進步和對疾病基因組成的更好理解的推動下，對有效治療和支持性護理服務的需求不斷成長是一個關鍵的成長要素。策略夥伴關係和合作研究工作正在為創新藥物配方和治療方法開闢新途徑，為相關人員提供有利的機會。然而，高昂的治療成本、臨床測試的複雜性和嚴格的監管要求等限制帶來了重大挑戰。此外，MDS 的異質性使治療效果和市場可預測性變得複雜。

為了利用這些機會，公司應該專注於創新標靶治療、利用生物標記研究以及開發具有成本效益的診斷和治療方法，以改善患者的治療結果。了解區域市場動態和投資新興市場也被認為是有益的。需要透過相關人員的參與和教育措施來解決某些人群的有限患者入組和診斷不足等挑戰。基因檢測和精準醫學的創新具有開拓的潛力。最終，使產品開發與患者需求和市場要求保持一致對於確保在不斷變化的市場環境中持續成長和競爭優勢至關重要。研究和開發必須繼續優先考慮以患者為中心的方法，以提高整體市場的永續性和臨床成功。

市場動態：揭示快速發展的骨髓發育不良症候群市場的關鍵市場洞察

骨髓發育不良症候群市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加，此病發生率增加
    • 改善醫療服務以及幹細胞移植和放射線治療的進步
    • 新治療方法的可用性和可及性
  • 市場限制因素
    • 新療法的高成本
  • 市場機會
    • 開發強大的藥物管道
    • 報銷政策等政府支持措施
  • 市場問題
    • 新療法的複雜性和異質性

波特的五力：駕馭骨髓發育不良症候群市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨髓發育不良症候群市場的外部影響

外部宏觀環境因素在塑造骨髓發育不良症候群市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解骨髓發育不良症候群市場的競爭格局

對骨髓發育不良症候群市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：骨髓發育不良症候群市場的供應商績效評估

FPNV定位矩陣是評估骨髓發育不良症候群市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製骨髓發育不良症候群市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，骨髓發育不良症候群市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口增加和綜合症發生率增加
      • 改善醫療服務以及幹細胞移植和放射治療的進步
      • 新治療方法的可用性和可及性
    • 抑制因素
      • 新治療方法的高成本
    • 機會
      • 開發強大的藥物管道
      • 退費政策等政府支持措施
    • 任務
      • 新療法的複雜性和多樣性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章骨髓發育不良症候群市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的

第7章骨髓發育不良症候群市場：依藥物類別

  • 介紹
  • 烷化劑
  • 細胞毒性抗生素
  • 拓樸異構酶抑制劑

第8章北美和南美骨髓發育不良症候群市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太骨髓發育不良症候群市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲骨髓發育不良症候群市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Bellicum Pharmaceuticals
  • BioLineRx Ltd.
  • BluePoint Laboratories
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Johnson & Johnson
  • MEI Pharma Inc.
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3A8C0

The Myelodysplastic Syndrome Market was valued at USD 2.59 billion in 2023, expected to reach USD 2.84 billion in 2024, and is projected to grow at a CAGR of 10.07%, to USD 5.07 billion by 2030.

Myelodysplastic Syndrome (MDS), a group of diverse bone marrow disorders, is characterized by ineffective hematopoiesis leading to blood cell abnormalities. The analytical scope of this domain involves understanding its diagnostic methods, treatments, and patient demographics, essential for creating targeted marketing strategies. The necessity of research in MDS arises from its increasing prevalence, notably among the aging population, and the moderate survival rates which demand better therapeutic solutions. The application scope touches on pharmaceutical advancements, personalized medicine, and novel diagnostic technologies, while the end-use scope encompasses hospitals, cancer centers, and specialized clinics equipped to manage MDS treatment and care.

KEY MARKET STATISTICS
Base Year [2023] USD 2.59 billion
Estimated Year [2024] USD 2.84 billion
Forecast Year [2030] USD 5.07 billion
CAGR (%) 10.07%

Market insights reveal that the rising demand for effective therapeutics and supportive care services are key growth factors, driven by advancements in drug development and an increased understanding of the disease's genetic makeup. Strategic partnerships and collaborative research efforts are opening new avenues for innovative drug formulations and treatment methodologies, offering lucrative opportunities for stakeholders. However, limitations such as the high cost of treatment, the complexity of clinical trials, and stringent regulatory requirements pose significant challenges. Moreover, the heterogeneity of MDS complicates treatment efficacy and market predictability.

To harness these opportunities, businesses should focus on innovation in targeted therapies, leveraging biomarker research, and developing cost-effective diagnostics and treatments to improve patient outcomes. Understanding regional market dynamics and investing in emerging markets could also be beneficial. Challenges such as limited patient registries and underdiagnosis in certain populations need addressing through stakeholder engagement and educational initiatives. Innovations in genetic testing and precision medicine present untapped potential. Ultimately, aligning product development with patient needs and market requirements will be crucial for sustained growth and competitive advantage in the evolving MDS market landscape. Research and development must continue to prioritize patient-centric approaches to enhance overall market sustainability and clinical success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Myelodysplastic Syndrome Market

The Myelodysplastic Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population and increasing incidence of the syndrome
    • Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
    • Easy of availability and access to novel treatments
  • Market Restraints
    • High cost of novel therapeutics
  • Market Opportunities
    • Development of strong drug pipeline
    • Supportive government initiatives such as reimbursement policies
  • Market Challenges
    • Complexity and heterogeneity of novel treatment

Porter's Five Forces: A Strategic Tool for Navigating the Myelodysplastic Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Myelodysplastic Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Myelodysplastic Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Myelodysplastic Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Myelodysplastic Syndrome Market

A detailed market share analysis in the Myelodysplastic Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Myelodysplastic Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Myelodysplastic Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Myelodysplastic Syndrome Market

A strategic analysis of the Myelodysplastic Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Myelodysplastic Syndrome Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bellicum Pharmaceuticals, BioLineRx Ltd., BluePoint Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Dr. Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson, MEI Pharma Inc., Novartis AG, Onconova Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Myelodysplastic Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Drug Class, market is studied across Alkylating Agents, Cytotoxic Antibiotics, and Topoisomerase Inhibitors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population and increasing incidence of the syndrome
      • 5.1.1.2. Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
      • 5.1.1.3. Easy of availability and access to novel treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of novel therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of strong drug pipeline
      • 5.1.3.2. Supportive government initiatives such as reimbursement policies
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity and heterogeneity of novel treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Myelodysplastic Syndrome Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Parenteral

7. Myelodysplastic Syndrome Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Cytotoxic Antibiotics
  • 7.4. Topoisomerase Inhibitors

8. Americas Myelodysplastic Syndrome Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Myelodysplastic Syndrome Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Myelodysplastic Syndrome Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Bellicum Pharmaceuticals
  • 4. BioLineRx Ltd.
  • 5. BluePoint Laboratories
  • 6. Bristol-Myers Squibb Company
  • 7. Celgene Corporation
  • 8. Dr. Reddy's Laboratories
  • 9. Eli Lilly and Company
  • 10. Johnson & Johnson
  • 11. MEI Pharma Inc.
  • 12. Novartis AG
  • 13. Onconova Therapeutics, Inc.
  • 14. Otsuka Pharmaceutical Co., Ltd.
  • 15. Sun Pharmaceutical Industries Inc.
  • 16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. MYELODYSPLASTIC SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MYELODYSPLASTIC SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MYELODYSPLASTIC SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023